These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 19422924)

  • 1. Exploratory drug safety: a discovery strategy to reduce attrition in development.
    Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
    J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1131-6. PubMed ID: 24368175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical Safety and Toxicology.
    Stark C; Steger-Hartmann T
    Handb Exp Pharmacol; 2016; 232():261-83. PubMed ID: 26489827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A framework to assess the translation of safety pharmacology data to humans.
    Valentin JP; Bialecki R; Ewart L; Hammond T; Leishmann D; Lindgren S; Martinez V; Pollard C; Redfern W; Wallis R
    J Pharmacol Toxicol Methods; 2009; 60(2):152-8. PubMed ID: 19616110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are multimetabolite methods fit-for-purpose for supporting toxicology studies?
    Smith G
    Bioanalysis; 2011 Dec; 3(24):2701-4. PubMed ID: 22185267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety pharmacology investigations in toxicology studies: an industry survey.
    Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
    J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
    Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.